Drug intelligence / Profile preview

TerXT LAI

Development stage
Preclinical
Lead developer
Terran Biosciences
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Intramuscular, Subcutaneous
01

Overview

TerXT LAI is a long-acting injectable (LAI) prodrug formulation of the xanomeline and trospium combination, currently under development by Terran Biosciences (a Turret Capital Management portfolio company) for the treatment of schizophrenia. It utilizes the same pharmacology as KarXT (xanomeline/trospium), acting as a dual M1/M4 muscarinic receptor agonist to address psychotic symptoms while employing trospium, a peripheral antimuscarinic, to mitigate systemic side effects. TerXT LAI is designed to improve patient compliance and provide sustained therapeutic levels compared to oral formulations. It is currently in the preclinical/IND-enabling stage, pursuing an accelerated 505(b)(2) regulatory pathway.

Other names
xanomeline + trospium long-acting injectable
02

Targets

M1 (Muscarinic acetylcholine receptor M1)mAChR (Muscarinic acetylcholine receptor M1–M5)CHRM4 (M4)

Beyond the preview

Go deeper on TerXT LAI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TerXT LAI.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call